ϟ
DOI: 10.1155/1998/925346
¤ OpenAccess: Gold
This work has “Gold” OA status. This means it is published in an Open Access journal that is indexed by the DOAJ.
The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving Forward to New Concepts
Abr Thomson,Naoki Chiba,David Armstrong,Gervais Tougas,R. H. Hunt
Medicine
GERD
Disease
1998
Gastroesophageal reflux disease (GERD) is a disease with serious consequences that may result in significant impairment in quality of life and disease morbidity. Across all grades of severity of symptoms and severity of underlying esophageal disease, proton pump inhibitors (PPIs) provide therapeutic gains over prokinetics (PKs) or H 2 receptor antagonists (H 2 RAs). The potential cost effectiveness of using medications with higher acquisition costs that may lower health care costs overall is often disregarded when conducting cost comparisons with medications having lower 'up-front' costs. Limiting therapy to less effective agents condemns many patients to protracted suffering, repeated physician visits and needless reinvestigation of symptoms that could have been resolved by appropriate initial therapy. Based on current data, use of any classification of symptom severity as a basis for selecting one class of therapeutic agents over another for first line therapy (ie PKs, H 2 RAs for 'mild' GERD, versus a PPI for 'severe' disease) is unwarranted.
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving Forward to New Concepts” is a paper by Abr Thomson Naoki Chiba David Armstrong Gervais Tougas R. H. Hunt published in 1998. It has an Open Access status of “gold”. You can read and download a PDF Full Text of this paper here.